

United States Patent and Trademark Office
- Sales Receipt -

03/29/2006 TBARDEN 00000002 503231 10536686

01 FC:1202	200.00 DA
02 FC:1203	360.00 DA

United States Patent and Trademark Office

- Sales Receipt -

Adjustment date: 03/29/2006 TBARDEN

06/03/2005 LLANDGRA 00000024 503231 10536686

04 FC:1614 400.00 CR



Express Mail Label No.: ED 114328690 US
Attorney Docket No.: 100861-1P US

107536686

JC20 Rec'd PCT/PTO 27 MAY 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gravestock <i>et al</i>	Filed: Herewith
Application No.: Not yet assigned	Attorney Docket No.: 100861-1P US
PCT Application No.: PCT/GB2003/005087	Examiner: Not yet assigned
Title: OXAZOLIDINONE AND / OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS	

Mail Stop PCT
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

This preliminary amendment is being filed simultaneously with the filing of the above-identified U.S. National Stage application. Prior to calculation of the claim fees and examination of the application on its merits, please amend it as follows:

Amendments to the specification begin on page 2 of this paper.

Amendments to the claims begin on page 3 of this paper.

Remarks/Arguments begin on page 4 of this paper.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No.: ED 114328690 US

Date of Deposit: May 28, 2005

Fee Applied Only

Remarks/Arguments


Applicants have amended the specification to incorporate the priority claim.

The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. Thus, claims 1, 10, 15, 16, 17, 18, 18, and 19 are as originally presented. Claims 2, 3, 4, 5, 6, 7, 8, 9, 11, and 14 are currently amended. Claims 12 and 13 are cancelled. No new matter has been added by these amendments. Also, the above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application. Applicants further believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No.

50-3231, referencing Attorney Docket No. 100856.

Respectfully submitted,



Name: Heidi Berven
Dated: May 28, 2005
Reg. No.: 48,951
Phone No.: 781-839-4336
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 01760